Anticoagulant Therapy During Pacemaker Implantation (FINPAC)

This study has been completed.
Sponsor:
Collaborators:
Satakunta Central Hospital
Oulu University Hospital
Tampere University Hospital
Information provided by (Responsible Party):
Juhani Airaksinen, University of Turku
ClinicalTrials.gov Identifier:
NCT00479362
First received: May 25, 2007
Last updated: September 14, 2012
Last verified: September 2012

May 25, 2007
September 14, 2012
September 2005
September 2012   (final data collection date for primary outcome measure)
Measure: rate of haemorrhagic and thromboembolic complications [ Time Frame: within first four weeks ] [ Designated as safety issue: Yes ]
Measure: rate of haemorrhagic and thromboembolic complications [ Time Frame: within first four weeks ]
Complete list of historical versions of study NCT00479362 on ClinicalTrials.gov Archive Site
Not Provided
Measure:rate of complications in venography-assisted subclavian vein venipuncture [ Time Frame: Perioperative phase ]
Not Provided
Not Provided
 
Anticoagulant Therapy During Pacemaker Implantation
Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation

There are no established guidelines regarding interruption of warfarin anticoagulant therapy prior to surgical implantation of cardiac pacemakers. Continuing the anticoagulant could potentially result in increased bleeding complications from the implantation surgery, whereas discontinuing the anticoagulant could predispose the patient to blood clots and strokes. In this study we intend to randomly assign warfarin-treated patients either into interrupted or continued warfarin therapy prior to pacemaker implantation with the purpose of establishing the rate of complication in these groups. Our hypothesis is that a cardiac pacing device can be safely implanted without discontinuation of the anticoagulant therapy.

Despite greatly increased utilization of pacemaker and internal cardioverter-defibrillator (ICD) therapy for various indications in recent years, there are relatively few published studies on bleeding complications associated with the implantation of these devices. The purpose of our study is to assess the incidence and severity of hemorrhagic complications resulting from pacemaker and ICD implantation in patients treated with oral anticoagulant warfarin or acetyl salicylic acid.

There are no unified guidelines regarding warfarin use during pacemaker implantation. A case by case approach is commonly employed regarding whether to interrupt or to continue anticoagulant therapy prior to the procedure. Interrupting the therapy may expose the patient to thromboembolic complications, whereas continuing it can increase the risk of perioperative bleeding. Thus, either approach could potentially increase patient morbidity and prolong the hospital stay. Therefore, an evidence based choice of an appropriate approach in preparing the anticoagulant-treated patients for pacemaker implantation could have significant impact on both patient safety and over-all procedural cost.

We intend to assess the rate of hemorrhagic and thrombotic complications as well as the length of hospital stay associated with pacemaker or ICD implantation in patients randomized either to continue or to interrupt their warfarin treatment. One control group will be formed of pacemaker-receiving patients on acetyl salicylic acid as well as one group of patients on no medications affecting the coagulation system or thrombocyte aggregation. Potential risk factors for bleeding or thromboembolic complications will be searched.

A total of 400 patients will be recruited into this multicenter study conducted at five hospitals in Finland. Warfarin users (n=200) will be randomly allocated into two groups: A. uninterrupted warfarin therapy maintained at accepted intensity (INR 2 to 3), and B. interruption of warfarin 2 days prior to device implantation. Control groups will comprised as described above with one hundred patients in each. The end-points of the study are: occurrences of major bleeding, haemorrhages and hematomas at pacemaker pocket, utilization of adjunctive therapies to control bleeding (e.g. Vitamin K or Fresh frozen plasma), need for surgical wound revision and thromboembolic complications. The duration of hospital stay will also be recorded. At two of the centres (Turku University Hospital and Satakunta Central Hospital) all patients will also be randomly assigned into two groups in which the implantation procedure will either be or not be guided by venous angiography.

Patients willing to participate in the study will receive both verbal and written information on the study and they will be asked to sign an informed consent. All devices will be implanted in a normal fashion according to generally accepted clinical guidelines. A variety of clinical and laboratory variables will be recorded in each study group to identify risk factors for bleeding and thromboembolism.

The aims of our study are to establish among patients implanted with pacemakers (1) whether uninterrupted warfarin therapy will increase the rate and severity of bleeding complications, (2) whether interruption of warfarin results in increased thromboembolic events, (3) whether aspirin treatment increases bleeding complications compared, and we also seek to identify factors predisposing to haemorrhagic complications.

Our main hypothesis is that a cardiac pacing device can be safely implanted without discontinuation of the anticoagulant therapy.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Primary Purpose: Treatment
  • Hemorrhage
  • Thrombosis
  • Embolism
  • Drug: Warfarin
    Warfarin is either interrupted or uninterrupted prior to device implantation
    Other Names:
    • Marevan, ATC code B01AA03
    • Marevan Forte, ATC code B01AA03
  • Drug: Aspirin
    Aspirin is continued without interruption prior to device implantation
    Other Names:
    • Acethyl Salcylic Acid
    • Primaspan, ATC code B01AC06
    • Disperin, ATC code B01AC06
    • Aspirin Cardio, ATC code B01AC06
  • Device: Permanent pacemaker
    Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
    Other Name: Pacing Device Implantation
  • Device: Implantable Cardioverter-defibrillator
    Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
    Other Name: ICD
  • Experimental: 1 Warfarin Uninterrupted
    Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
    Interventions:
    • Drug: Warfarin
    • Device: Permanent pacemaker
    • Device: Implantable Cardioverter-defibrillator
  • Active Comparator: 2 Warfarin Interrupted
    Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
    Interventions:
    • Drug: Warfarin
    • Device: Permanent pacemaker
    • Device: Implantable Cardioverter-defibrillator
  • Sham Comparator: 3 Aspirin Group
    Patients with aspirin therapy during implantation
    Interventions:
    • Drug: Aspirin
    • Device: Permanent pacemaker
    • Device: Implantable Cardioverter-defibrillator
  • 4 No Antithrombotic Group
    No antithrombotic treatment during operations
    Interventions:
    • Device: Permanent pacemaker
    • Device: Implantable Cardioverter-defibrillator
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
447
September 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • all patients admitted for implantation of a first permanent cardiac pacing device are eligible

Exclusion Criteria:

  • known coagulation disorder or bleeding diathesis
  • contraindications for pacing device implantation
  • mechanical prosthetic heart valve
  • other absolute contraindication to interrupt warfarin
  • INR (international normalized ratio) above 3.0 2 days prior to implantation
  • significant anemia (hemoglobin less than 100 g/L)
  • warfarin interrupted before randomization and INR subtherapeutic (below 2.0)
  • not to be randomized to venography: contraindications to radiographic contrast dye
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT00479362
FINPAC, TAHD-VARF (Former Protocol ID), TV001
No
Juhani Airaksinen, University of Turku
University of Turku
  • Satakunta Central Hospital
  • Oulu University Hospital
  • Tampere University Hospital
Study Director: Juhani Airaksinen, MD University of Turku, Turku University Hospital
Principal Investigator: Petri Korkeila, MD Turku University Hospital
University of Turku
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP